Evaluation of A Clinical Diagnostic Test for CRDS
Key facts
- Who runs it
- Population Health Research Institute
- Where
- Boston, Rochester, San Francisco, and Seattle, United StatesSee the 4 sitesAlso in 6 other countries, 17 sites
- Trial code
- Status
- Recruiting
- People taking part
- 400 people, planned
- Started
- 2 Feb 2023
- Expected to end
- Mar 2028
- Type of study
- Interventional
- Treatments tested
- Pacing
- Record updated
- 9 November 2026
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Presence of an RyR2 variant confirmed to be loss-of-function on in vitro testing
- Satisfy a clinical phenotype consistent with the Expert Consensus Statement
- Presence of a confirmed or presumed pathogenic gain-of-function RyR2 variant OR homozygous or compound heterozygous for likely pathogenic/pathogenic CASQ2 variants
- Cardiac arrest requiring cardioversion or defibrillation that remains unexplained following an ECG, echocardiogram, coronary assessment, cardiac MRI, and exercise treadmill test
- Undergone genetic testing that includes screening of RyR2*
- Undergoing an invasive electrophysiology study
Who cannot take part
- Use of a Class I or Class III anti-arrhythmic drug at the time of the EP study
- Known obstructive coronary artery disease (existing coronary stenosis >50%)
- Use of a QT prolonging medication, aside from flecainide, at the time of the burst pacing maneuvers; Cohort 3: Survivors of Unexplained Cardiac Arrest (UCA)
- Use of a QT prolonging medication at the time of the burst pacing maneuvers; Among survivors of UCA that possess a rare RyR2 variant in the absence of a CPVT phenotype, in vitro functional testing will be performed in order to confirm it is not loss- or gain-of-function (and will be arranged through the laboratory of Dr. Wayne Chen at the University of Calgary); Cohort 4: SVT controls
- Long QT syndrome
- Use of a QT prolonging medication at the time of the EP study
- Unable to provide informed consent; Cohort 2: Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Cases
- Unable to provide informed consent
- Unable to provide informed consent
- Ventricular cardiomyopathy
- Ventricular pre-excitation
- Unable to provide informed consent
Other criteria
- Cohort 1: Calcium Release Deficiency Syndrome (CRDS) Cases
Where in United States
Also in 6 other countries, 17 sites
- Boston Children's HospitalBoston, United StatesContact: Project ManagerTaking people
- Mayo ClinicRochester, United StatesContact: Project ManagerTaking people
- University of CaliforniaSan Francisco, United StatesContact: Project ManagerTaking people
- University of WashingtonSeattle, United StatesContact: Project ManagerTaking people
About the trial
What the trial wants to find out
Calcium Release Deficiency Syndrome (CRDS) is a novel inherited arrhythmia syndrome secondary to RyR2 loss-of-function that confers a risk of sudden cardiac death. Diagnosis of CRDS presently requires cellular-based in vitro confirmation that an RyR2 variant causes loss-of-function. We hypothesize that CRDS can be diagnosed clinically through evaluation of the repolarization response to brief tachycardia, mediated by cardiac pacing, and a subsequent pause.
The group in the trial
- PacingTreatment being tested
Separate ventricular and atrial pacing trains will be administered at different cycle lengths and the ventricular repolarization response on the first sinus beat following the subsequent pause will be evaluated.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of a Clinical Diagnostic Test for Calcium Release Deficiency Syndrome: The DIAGNOSE CRDS Study
- Publications
- Record updated
- 9 November 2026